LAWRENCE, Mass., Feb. 2, 2015 /PRNewswire/ -- NxStage®
Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of
dialysis products, will host an educational panel discussion today
on home nocturnal hemodialysis therapy ("nocturnal") during the
Annual Dialysis Conference (ADC) in New
Orleans. A panel moderator will lead a discussion for
dialysis providers on the NxStage System One™'s recent U.S. Food
and Drug Administration's (FDA) clearance for nocturnal therapy,
and its significant and wide-reaching clinical and lifestyle
benefits. Panelists will highlight their applications of best
demonstrated practices, offer insight on applying these tactics to
build and develop nocturnal programs and expand access to this
important therapy option for patients. Featured panelists are Dr.
Robert Lockridge of Lynchburg
Nephrology Physicians, Dr. Christopher
Hoy of DCI Rubin Dialysis, and Lisa
Koester, CNN-NP Renal Nurse Practitioner of Washington University School of Medicine, Renal
Division.
In December 2014, the FDA cleared
the company's System One to perform hemodialysis overnight while
the patient is at home sleeping, known as nocturnal therapy.
NxStage's System One is the first and only hemodialysis machine
cleared by the FDA for this indication. A longer,
overnight therapy allows greatly expanded flexibility in dialysis
dose and schedule, better enabling physicians to match dialysis
prescription to each patient's healthcare and lifestyle needs. By
performing therapy while sleeping, patients are able to clear their
schedules for other activities during the day.
"We've proven over the years that nocturnal therapy can
drastically reduce the perceived time on dialysis," said Dr.
Lockridge. "Through this panel discussion, I hope to assure my
colleagues in nephrology that providing access to this important
therapy option can make a significant difference in their patients'
lives."
"These panelists have almost 70 years of experience
collectively, and have blazed the trail for others with best
demonstrated practices for nocturnal therapy," said NxStage
President, Joe Turk. "ADC is a
tremendous opportunity to finally promote what these leading
nephrologists have practiced, and clinically tested, for some time.
This first-of-its-kind clearance will provide patients with access
to the enhanced clinical and lifestyle benefits made possible with
nocturnal therapy."
For more information on the event and the System One, please
visit www.nxstage.com.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
Additional Risks Associated with Nocturnal Home Hemodialysis
Therapy
The NxStage System One may be used at night while
the patient and care partner are sleeping. Certain risks associated
with hemodialysis treatment are increased when performing nocturnal
therapy due to the length of treatment time and because therapy is
performed while the patient and care partner are sleeping. These
risks include, but are not limited to, blood access disconnects and
blood loss during sleep, blood clotting due to slower blood flow or
increased treatment time or both, and delayed response to alarms
when waking from sleep. Ancillary anticoagulant infusion pumps and
fluid leak detection devices may be used to decrease certain risks
for home hemodialysis treatments performed at any time, but NxStage
requires the use of fluid leak detectors to identify leaks from the
vascular access, Cycler and Cartridge when performing nocturnal
therapy with the NxStage System One.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company, headquartered
in Lawrence, Massachusetts,
USA, that develops, manufactures and markets innovative
products for the treatment of ESRD and acute kidney failure. For
more information on NxStage and its products, please visit the
Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and
Exchange Commission, including the Quarterly Report on Form 10-Q
for the quarter ended September 30, 2014. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-hosts-panel-discussion-on-home-nocturnal-hemodialysis-at-2015-annual-dialysis-conference-300028881.html
SOURCE NxStage Medical Inc.